Watchlist Price Alert

Fate Therapeutics Inc. (FATE)

NASDAQ: FATE · Real-Time Price · USD

1.05

0.04 (3.96%)

At close: May 16, 2025, 3:59 PM

1.08

2.37%

After-hours: May 16, 2025, 05:23 PM EDT

3.96% (1D)

Bid	1
Market Cap	120.94M
Revenue (ttm)	13.34M
Net Income (ttm)	-175.88M
EPS (ttm)	-1.64
PE Ratio (ttm)	-0.64
Forward PE	-0.72
Analyst	Hold

Ask	1.2
Volume	1,834,751
Avg. Volume (20D)	2,437,072
Open	1.01
Previous Close	1.01
Day's Range	1.00 - 1.12
52-Week Range	0.66 - 5.92
Beta	2.33

About FATE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol FATE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for FATE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Fate Therapeutics has released their quartely earnings on May 13, 2025:

Revenue of $1.63M exceeds estimates by $429K, with -15.38% YoY decline.

EPS of -0.32 exceeds estimates by 0.14, with 31.91% YoY growth.

Why Price Moved

1 month ago

+21.17%

Fate Therapeutics shares are trading higher after... Unlock content with Pro Subscription

5 months ago

+2.64%

Fate Therapeutics shares are trading higher after the company unveiled its Phase 1 data for FT819 CAR T-cell therapy in systemic lupus erythematosus. Its first three patients showed rapid and sustained b-cell depletion with no dose-limiting toxicities.

News

4 days ago · zacks.com

Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus

FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.

5 days ago · zacks.com

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.47 per share a year ago.

1 week ago · seekingalpha.com

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector

I've had a mixed experience with Fate Therapeutics, initially noting rallies but later observing a significant 75% decline, questioning market enthusiasm. Revisiting FATE after a year, I aim to determ...

1 month ago · zacks.com

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus.

2 months ago · zacks.com

FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus

FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.

2 months ago · zacks.com

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.45 per share a year ago.